![]() |
市場調查報告書
商品編碼
1722901
2025 年至 2033 年藥物篩選市場規模、佔有率、趨勢及預測(按產品和服務、樣本類型、最終用戶和地區)Drug Screening Market Size, Share, Trends and Forecast by Product and Service, Sample Type, End User, and Region, 2025-2033 |
2024 年全球藥物篩選市場規模為 68.7 億美元。展望未來,預計到 2033 年市場規模將達到 120.3 億美元,2025 年至 2033 年的複合年成長率為 6.37%。北美目前佔據市場主導地位,到 2024 年市佔率將超過 51%。北美地區的成長受到嚴格的工作場所法規、先進的測試技術和不斷提高的藥物濫用意識的推動。
主要市場促進因素:由於藥物篩選準確且能提供自發性結果,因此對藥物篩選的需求不斷增加,這主要推動了市場的成長。此外,世界各地藥物濫用案件的增加也推動了全球市場的發展。
主要市場趨勢:將自動化、人工智慧 (AI) 和分子診斷等先進技術與藥物篩選測試相結合,以簡化工作流程、減少人為錯誤並加強測試,這是推動市場成長的重要關鍵趨勢之一。
競爭格局:一些領先的藥物篩選市場公司包括雅培實驗室、Alfa Scientific Designs Inc.、Bio-Rad Laboratories Inc.、Dragerwerk AG & Co. KGaA、Laboratory Corporation of America Holdings、Lifeloc Technologies Inc.、Omega Laboratories Inc.、OraSure Technologies Inc.、Scorpemedics Corporation、Questemnosics Corporation、Questagnostics Incorporers Incorporers.Scorpionedics Corporation、Psychagnostics)公司。
地理趨勢:根據報告,北美是最大的藥物篩選市場。該地區的成長可以歸因於藥物濫用案件的不斷升級、毒販數量的增加以及處方藥黑市交易的增加。
挑戰與機會:藥物篩選市場面臨著與開發準確可靠的測試、克服假陽性和假陰性以及解決樣本收集和測試程序相關的隱私和道德問題相關的障礙。機會在於整合人工智慧和機器學習等先進技術進行資料分析,以及開發攜帶式和即時檢測設備以實現便利的篩檢應用。
毒品和酒精消費量上升
藥物消費量的增加導致對藥物篩檢產品的需求增加。例如,根據2023年歐洲毒品報告,歐盟約有8,340萬成年人(29%)據稱至少使用過一次非法藥物。大麻是歐洲最主要的非法毒品,根據全國調查,預計 2022 年歐洲成年人使用大麻的人數將達到 8%。因此,大量人口吸食毒品,影響個人生活,並可能增加對藥物篩檢的需求,從而支持藥物篩檢市場的近期價格。此外,預計藥物和酒精的使用量增加以及治療需求將推動醫院對藥物篩檢的需求增加。例如,根據政府發布的國家統計數據。英國,截至2023年12月,2022年4月至2023年3月期間,約有290,635名成年人獲得了藥物濫用問題支持。與去年的約 289,215 人相比,這一數字略有增加。此外,同一消息來源還表示,2022 年至 2023 年接受治療的成年人數量約為。 137,749,高於前兩年的130,490和133,704。預計藥物濫用人數的大幅增加將推動藥物篩選市場的需求。
政府法規
多項法律法規要求在各個領域進行藥物和酒精測試,這些法律的實施增加了對藥物篩檢產品和設備的需求。例如,2022 年 11 月,聯邦汽車運輸安全管理局 (FMCSA) 發布了概述藥物和酒精測試要求的更新。這些規定具體規定了接受檢測的個人、檢測頻率以及觸發檢測的情況。此外,法規還限制雇主和服務代理使用和披露敏感的藥物和酒精測試資訊,以保護員工的隱私。除了監管框架外,各國政府部門也在採取措施幫助嚴重吸毒者和遭受藥物濫用困擾的個人,這進一步推動了藥物篩檢市場佔有率的成長。例如,印度政府發起了「Nasha Mukt Bharat Abhiyaan」項目,旨在透過各種活動(如意識提升計劃)接觸大眾並傳播有關藥物濫用的意識。同樣,加拿大政府當局也在投資禁毒策略項目,幫助吸毒者擺脫藥物濫用。例如,加拿大阿爾伯塔省卡加利約翰霍華德協會致力於幫助13至24歲因吸毒而面臨輟學風險的青少年。
測試技術的進步
藥物篩選技術的不斷進步,例如快速檢測試劑盒、實驗室檢測和即時診斷設備,透過提供更快、更準確、更具成本效益的篩選解決方案,進一步推動了市場的成長。此外,藥物篩選技術的不斷改進正在提高準確性和可靠性,降低假陽性或假陰性的可能性,確保測試結果的可靠性並最大限度地減少確認測試的需要,從而簡化篩選流程並降低成本。例如,2024 年 2 月,Mobile Health 在紐約診所推出了一項新的快速藥物檢測服務,方便雇主輕鬆篩選和僱用候選人。同樣,2023 年 10 月,ProciseDx Inc. 獲得了 FDA 的批准,可對阿達木單抗(Humira 和生物學名藥 Amgevita)和英夫利昔單抗(Remicade 和生物學名藥 Inflectra 和 Renflexis)進行治療藥物監測 (TDM) 測試。這些檢測方法稱為 Procise ADL 和 Procise IFX,用於量化正在服用阿達木單抗 (ADL) 和英夫利西單抗 (IFX) 的發炎性腸道疾病 (IBD) 患者的藥物含量。預計未來幾年新藥測試和儀器的批准增加將推動藥物篩選市場收入的成長。
The global drug screening market size was valued at USD 6.87 Billion in 2024. Looking forward, it is estimated that the market to reach USD 12.03 Billion by 2033, exhibiting a CAGR of 6.37% from 2025-2033. North America currently dominates the market, holding a market share of over 51% in 2024. The growth of the North American region is driven by stringent workplace regulations, advanced testing technologies, and increased substance abuse awareness.
Major Market Drivers: Increasing demand for drug screening as it is accurate and provides spontaneous results is primarily driving the growth of the market. Furthermore, the rising cases of substance abuse around the world are also propelling the global market.
Key Market Trends: The integration of advanced technologies such as automation, artificial intelligence (AI), and molecular diagnostics with drug screening tests to streamline workflows, reduce human errors, and enhance testing is acting as one of the significant key trends, bolstering the market growth.
Competitive Landscape: Some of the leading drug screening market companies include Abbott Laboratories, Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Dragerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Lifeloc Technologies Inc., Omega Laboratories Inc., OraSure Technologies Inc., Psychemedics Corporation, Quest Diagnostics Incorporated, Siemens AG, and Thermo Fisher Scientific Inc., among others.
Geographical Trends: According to the report, North America is the largest market for drug screening. The growth of the region can be attributed to the escalating cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs.
Challenges and Opportunities: The drug screening market faces hurdles related to the development of accurate and reliable tests, overcoming false positives and negatives, and addressing privacy and ethical concerns regarding sample collection and testing procedures. Opportunities lie in the integration of advanced technologies such as AI and machine learning for data analysis and the development of portable and point-of-care testing devices for convenient and rapid screening applications.
Rise in Drug and Alcohol Consumption
The increasing consumption of drugs is resulting in an increased demand for drug-screening products. For instance, according to the 2023 European Drug Report, approximately 83.4 million adults (29%) in the European Union have reportedly used illicit drugs at least once. Cannabis is the predominant illicit drug consumed in Europe, with an estimated 8% of European adults using it in 2022, based on national surveys. Thus, a high number of the population consumes drugs, which impacts the lives of individuals and is likely to increase demand for drug screening, thereby bolstering the drug screening market's recent price. Additionally, the rising utilization of drugs and alcohol, along with the need for treatment, is anticipated to drive up the demand for drug screening in hospitals. For instance, as per National statistics published by GOV. UK, in December 2023, between April 2022 and March 2023, around 290,635 adults received support for substance use issues. This is a small rise compared to the previous year, around 289,215. Moreover, the same source stated that the number of adults entering treatment from 2022 to 2023 was approx. 137,749, which is higher than the previous two years' figures of 130,490 and 133,704. Such a significant rise in the number of people undergoing substance use is anticipated to propel the drug screening market demand.
Government Regulations
Several laws and regulations mandate drug and alcohol testing in various sectors, and the implementation of such laws is augmenting the demand for drug-screening products and devices. For instance, in November 2022, the Federal Motor Carrier Safety Administration (FMCSA) released updates outlining the drug and alcohol testing requirements. These regulations specify the individuals subject to testing, the frequency of testing, and the circumstances triggering testing. Additionally, the regulations safeguard employee privacy by limiting the use and disclosure of sensitive drug and alcohol testing information by employers and service agents. Besides the regulatory framework, government authorities of various nations are also taking initiatives to help severe addicts and individuals suffering from drug abuse, which is further propelling the drug screening market share. For instance, Nasha Mukt Bharat Abhiyaan is a program by the Indian Government that intends to reach out to the masses and spread awareness about substance abuse through various activities like awareness generation programs. Similarly, the government authorities of Canada are also investing in anti-drug strategy projects to help people with addiction come out of substance abuse. For example, the Calgary John Howard Society in Alberta, Canada, focuses on assisting youths aged 13 to 24 who face the risk of school dropout due to drug addiction.
Advancements in Testing Technologies
Ongoing advancements in drug screening technologies, such as rapid testing kits, laboratory-based assays, and point-of-care devices, are further driving the market growth by offering faster, more accurate, and cost-effective screening solutions. Moreover, the continuous improvement of drug screening technologies is resulting in enhanced accuracy and reliability and reduced likelihood of false positives or false negatives, ensuring confidence in test results and minimizing the need for confirmatory testing, thereby streamlining the screening process and reducing costs. For instance, in February 2024, Mobile Health introduced a new rapid drug testing service in New York clinics for employers to screen and hire candidates easily. Similarly, in October 2023, ProciseDx Inc. received de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis). These assays, called Procise ADL and Procise IFX, are used to quantify adalimumab (ADL) and infliximab (IFX) in patients suffering from inflammatory bowel diseases (IBD) who are taking these drugs. Increasing approval of new drug tests and instruments is anticipated to propel the drug screening market revenue in the coming years.
Rapid testing devices represented the largest segment
The drug screening market report has provided a detailed breakup and analysis of the drug screening market based on the product and service. This includes equipment (immunoassay analyzers, chromatography instruments, and breath analyzers); rapid testing devices (urine testing devices and oral fluid testing devices); consumables (assay kits, sample collection cups, calibrators and controls, and others); and laboratory services. According to the report, rapid testing devices (urine testing devices and oral fluid testing devices) represented the largest segment.
Rapid drug screening test devices are portable, easy-to-use tools designed for quick detection of drugs in various sample types, such as urine, saliva, or blood. These devices offer several benefits, including rapid results within minutes, enabling on-the-spot decision-making in scenarios like workplace testing or roadside screening. Their simplicity allows for minimal training requirements, making them accessible to a wide range of users. Moreover, rapid tests are cost-effective, reducing the need for laboratory analysis and turnaround time. For instance, Drager, a German company based in Lubeck that makes breathing and protection equipment, gas detection and analysis systems, and non-invasive patient monitoring technologies, introduced a rapid test named DrugTest 5000. In this test, saliva samples can be analyzed immediately for an accurate result on the spot. Furthermore, rapid screening devices play a crucial role in emergencies, aiding in the quick identification of drug intoxication or overdose for prompt medical intervention.
Urine samples accounted for the largest market share
As per the drug screening market overview, urine sample drug testing offers several benefits, making it a preferred method over other sample types in many scenarios. Firstly, urine testing is non-invasive and relatively easy to collect, minimizing discomfort and ensuring employee cooperation. Secondly, urine samples can detect a wide range of drugs and their metabolites, providing comprehensive screening capabilities. Thirdly, urine testing is cost-effective and suitable for high-volume testing, making it practical for workplace screening programs. Furthermore, urine testing is capable of detecting recent drug use, making it suitable for detecting impairment in safety-sensitive industries. Lastly, this testing is less susceptible to adulteration or tampering compared to other sample types, ensuring the integrity and reliability of test results.
Workplaces accounted for the largest market share
Drug screening tests in workplaces are conducted to detect the presence of drugs or alcohol in employees. These tests are typically performed as part of pre-employment screening, random testing, post-accident testing, or reasonable suspicion testing. The aim is to ensure a safe and productive work environment, minimize the risk of accidents and injuries, and deter substance abuse among employees.
North America (the United States and Canada) was the largest market for drug screening
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for drug screening.
Some of the factors driving the North America drug screening market included the growing cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs. Moreover, drug screening market statistics by IMARC indicate that the growing substance abuse rates in the region are bolstering the need for drug screening. For instance, in February 2023, according to an article published by the Pennsylvania State University, around 63% of adults aged 18 years and above were reported to alcohol consumption in the United States in 2022. Among these, males (66%) had higher alcohol consumption as compared to females (61%). Thus, the large number of alcohol consumers raises the need for drug-testing products and services and is augmenting the market growth in North America. Moreover, the government authorities of North America are mandating drug screening tests in various sectors, which is further catalyzing the market growth. For instance, in May 2023, the United States Department of Transportation regulated the drug testing program by including oral fluid testing to improve safety and reduce the chances of cheating involved with urine drug tests.
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
March 2024: bioXcelerate, a new and innovative health data science division of Optima Partners Limited, revealed a groundbreaking AI tool, which is set to accelerate the process of identifying and developing new drugs. The tool, known as PleioGraph, can analyze complex medical data 100 times faster than existing state-of-the-art methods used to detect biological networks that explain disease risk and inform drug discovery.
December 2023: Quest Diagnostics, one of the leading providers of diagnostic information services, unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.
October 2023: In India, Kerala police launched a rapid drug screening system that involves the utilization of a hand-held device, named the SoToxa Mobile Test System, and detects drug usage in 5 minutes.